ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2387

Lupus Damage Index Revision – Item Generation and Reduction Phases

Burak Kundakci1, Megan Barber2, Ann Clarke2, Sindhu Johnson3 and Ian Bruce4, 1Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, 2Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 3Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, 4Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast, Belfast, United Kingdom

Meeting: ACR Convergence 2025

Keywords: Damage Index, Outcome measures, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: The current Systemic Lupus Erythematosus Damage Index (SDI) is a robust instrument, but is limited by missing items, restricted applicability in pediatric patients, and outdated item definitions. A data-driven and expert/patient consensus-based project to develop a revised Systemic Lupus International Collaborating Clinics (SLICC)/ American College of Rheumatology (ACR), Damage Index (SDI) is underway supported by SLICC, ACR and the Lupus Foundation of America. Our objective was to report the item generation and item reduction phase results for developing a revised SDI.

Methods: Item generation included a literature review by Literature Review Groups and a Delphi exercise of international SLE experts and patients. Item reduction involved Delphi rounds where items with a median appropriateness score of ≤ 4 out of 9 were excluded. A 14-member Item Reduction Committee assessed the remaining items and removed those that did not reflect the damage construct, were excessively rare, or were not feasible to assess. The Clinical Domain Groups then refined the remaining items, and their definitions.

Results: The Delphi panel included 146 individuals from 35 countries. Item generation identified 226 initial candidate items. The Delphi exercise, review by the Item Reduction Committee and Clinical Domain Groups resulted in removal of 36, 126 and 25 items, respectively. This resulted in 39 items across 13 clinical domains. Eleven items from the original SDI, including chronic peritonitis, cranial neuropathy, mesenteric insufficiency, muscle atrophy or weakness, osteomyelitis, pancreatic insufficiency requiring enzyme replacement or with pseudocyst, pleural fibrosis, proteinuria, shrinking lung, skin ulceration (excluding thrombosis), and stricture or upper gastrointestinal tract surgery were removed. Several new items were proposed, such as growth failure/reduced final height and adrenal insufficiency. Sub-categorizing items based on severity or grade is proposed for 17 (43.6%) proposed items. Additionally, the Clinical Domain Groups developed definitions for each of the items, based on their clinical expertise, current evidence-based practice or specialty guidelines.

Conclusion: This data-driven and expert/patient consensus-based process has proposed 39 candidate items, some with sub-items, and with definitions for a revised SDI. Weighting of items and sub-items is now underway to increase the sensitivity and responsiveness of any new index.


Disclosures: B. Kundakci: None; M. Barber: AstraZeneca, 1, GlaxoSmithKlein(GSK), 1; A. Clarke: AstraZeneca, 2, Bristol-Myers Squibb(BMS), 2, GlaxoSmithKlein(GSK), 2, 5, Novartis, 2, Roche, 2; S. Johnson: None; I. Bruce: AstraZeneca, 2, Eli Lilly, 2, GlaxoSmithKlein(GSK), 2, Janssen, 5, Merck/MSD, 2, Novartis, 5, Otsuka, 5, UCB, 2.

To cite this abstract in AMA style:

Kundakci B, Barber M, Clarke A, Johnson S, Bruce I. Lupus Damage Index Revision – Item Generation and Reduction Phases [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/lupus-damage-index-revision-item-generation-and-reduction-phases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lupus-damage-index-revision-item-generation-and-reduction-phases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology